Medicare Advantage & Supplemental Insurance

Medicare Enroll America allows the A65+ audience an opportunity to shop Medicare insurance plans from multiple big-name insurers. The spot does exceptionally well during the Medicare Annual Enrollment Period, which lasts from Oct 15 - Dec 7 of each year. Malbis employs a more specific "year round" copy to run outside of AEP in order to target consumers who become eligible for Medicare outside of the standard enrollment period.

View the per-call payout and TV commercial for this offer and the others below. Call 1-800-500-3222 for instant access to the private offers page.

ACA & Short-Term Health Insurance

We are betting long on health insurance. With multiple advertisers covering every possible piece of ground, you can run this spot knowing that, no matter the season, the phones will ring. For a sure-fire win, run this spot during open enrollment each year from Nov 1 - Dec 15.

Knee & Back Brace

The Back & Knee Pain Center is a Malbis all-time favorite. This spot has been in action for nearly 5 years, generating tens of millions of dollars in ad revenue for national networks and TV stations.

Diabetic Testing Supplies

With only 13 mail-order, Medicare-approved diabetic testing supply companies in the U.S., this offer is a rare find. Although the per-call payout could be more aggressive, the offer is 24/7 and has a low buffer with no state restrictions. This is a sure-fire winner for all stations and nets. DTS was big-business for PI TV a decade ago and has made a resurgance again in 2017.

Osteoarthritis Pain Cream

Another Malbis exclusive offer! As the first PI agency to bring this offer to air, your network will find the response rate to be through the roof with an A50+ audience. With a liberal buffer, 24/7 and no state restrictions, our advertiser has a call appetite (and budget) to satisfy.

Final Expense Insurance

Our final expense brand, Senior Legacy Life, is a great performer for the A50+ crowd. This offer also performs well in overnight inventory. Also, we're working on a Sat-Sun 8a-8p solution that should be in place for Jan 1, 2018.

Small Business Cash Advance

The U.S. Small Business Funding Network connects small businesses with lenders that provide short-term loan solutions, such as factoring account receivables.

Heroin Treatment / Rehab

Malbis is successfully running the first ever targeted rehab spot. The opiod crisis in America has caused an even larger heroin (and fentynal) problem. This spot targets suburban white females, the new face of heroin usage.

Debt Relief

The "Action Financial" brand for debt relief has been with us for nearly a decade. Run this tried and true spot to an A25-54 demo for best results.

Medical Alert

The "Mobile Help" brand for the medical alert vertical has been a winner for many national networks and stations. Run this tried and true spot to an A50+ demo for best results.

Mesothelioma / Asbestosis

Malbis is currently creating the most aggressive meso payout to ever to hit TV. You'll be able to monetize asbestosis traffic and meso with in one spot. If you are currently running meso or asbestosis PI, call us now and let's talk about what's in store for meso in 2018.

Clinical Trials - New Patient Acquisition

If you've never tested a clinical trial spot on your PI inventory, you're in for a treat. Malbis is creating a network of buyers to accomplish contiguous U.S. coverage. High payouts and a virgin market make this offer a must-run for PI inventory. Talk to your Malbis rep today and let them know that you want this spot as soon as it's available!

Mass Tort - Xarelto / Pradaxa

Xarelto and Pradaxa are currently two big hiters in mass tort. We have attorneys in place to buy calls and a spot in production. Mark your calendars for March 1, 2018 and talk to your Malbis rep now.

Whole Life Insurance for Kids

Malbis is in the process of creating a network of whole life insurance call buyers. The offer will allow grandparents to purchase life insurance for their grandchildren. The plan accumulates cash value as the child ages. We are targeting a February 2018 launch date.